Literature DB >> 23851682

Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma.

Anusha-Preethi Ganesan1, Magnus Johansson, Brian Ruffell, Adam Yagui-Beltrán, Adam Beltran, Jonathan Lau, David M Jablons, Lisa M Coussens.   

Abstract

Immune cells comprise a substantial proportion of the tumor mass in human nonsmall cell lung cancers (NSCLC), but the precise composition and significance of this infiltration are unclear. In this study, we examined immune complexity of human NSCLC as well as NSCLC developing in CC10-TAg transgenic mice, and revealed that CD4(+) T lymphocytes represent the dominant population of CD45(+) immune cells, and, relative to normal lung tissue, CD4(+)Foxp3(+) regulatory T cells (Tregs) were significantly increased as a proportion of total CD4(+) cells. To assess the functional significance of increased Tregs, we evaluated CD8(+) T cell-deficient/CC10-TAg mice and revealed that CD8(+) T cells significantly controlled tumor growth with antitumor activity that was partially repressed by Tregs. However, whereas treatment with anti-CD25-depleting mAb as monotherapy preferentially depleted Tregs and improved CD8(+) T cell-mediated control of tumor progression during early tumor development, similar monotherapy was ineffective at later stages. Because mice bearing early NSCLC treated with anti-CD25 mAb exhibited increased tumor cell death associated with infiltration by CD8(+) T cells expressing elevated levels of granzyme A, granzyme B, perforin, and IFN-γ, we therefore evaluated carboplatin combination therapy resulting in a significantly extended survival beyond that observed with chemotherapy alone, indicating that Treg depletion in combination with cytotoxic therapy may be beneficial as a treatment strategy for advanced NSCLC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23851682      PMCID: PMC3774528          DOI: 10.4049/jimmunol.1301317

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  58 in total

Review 1.  IDO and tolerance to tumors.

Authors:  David H Munn; Andrew L Mellor
Journal:  Trends Mol Med       Date:  2004-01       Impact factor: 11.951

Review 2.  Policing pregnancy: Tregs help keep the peace.

Authors:  Andrew L Mellor; David Munn
Journal:  Trends Immunol       Date:  2004-11       Impact factor: 16.687

3.  Cyclin-dependent kinase inhibitor expression in pulmonary Clara cells transformed with SV40 large T antigen in transgenic mice.

Authors:  S M Magdaleno; G Wang; V L Mireles; M K Ray; M J Finegold; F J DeMayo
Journal:  Cell Growth Differ       Date:  1997-02

4.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

Authors:  S Onizuka; I Tawara; J Shimizu; S Sakaguchi; T Fujita; E Nakayama
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

5.  The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia.

Authors:  K R Schultz; J P Klarnet; R S Gieni; K T HayGlass; P D Greenberg
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

6.  Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.

Authors:  M D Pegram; D J Slamon
Journal:  Semin Oncol       Date:  1999-08       Impact factor: 4.929

7.  Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma.

Authors:  Michael Girardi; David Oppenheim; Earl J Glusac; Renata Filler; Allan Balmain; Robert E Tigelaar; Adrian C Hayday
Journal:  J Invest Dermatol       Date:  2004-03       Impact factor: 8.551

8.  CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer.

Authors:  Dylan Daniel; Christopher Chiu; Enrico Giraudo; Masahiro Inoue; Lee A Mizzen; N Randall Chu; Douglas Hanahan
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

9.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

10.  Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.

Authors:  Ping Yu; Youjin Lee; Wenhua Liu; Thomas Krausz; Anita Chong; Hans Schreiber; Yang-Xin Fu
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

View more
  56 in total

Review 1.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.

Authors:  Romain Remark; Christian Becker; Jorge E Gomez; Diane Damotte; Marie-Caroline Dieu-Nosjean; Catherine Sautès-Fridman; Wolf-Herman Fridman; Charles A Powell; Nasser K Altorki; Miriam Merad; Sacha Gnjatic
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

2.  IL-17 induces radiation resistance of B lymphoma cells by suppressing p53 expression and thereby inhibiting irradiation-triggered apoptosis.

Authors:  Qingshan Li; Xin Xu; Weijie Zhong; Qinghua Du; Bizhen Yu; Huabao Xiong
Journal:  Cell Mol Immunol       Date:  2014-12-29       Impact factor: 11.530

3.  Effects of etomidate and propofol on immune function in patients with lung adenocarcinoma.

Authors:  Jiapeng Liu; Wei Dong; Tao Wang; Liang Liu; Long Zhan; Yifei Shi; Jiange Han
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

4.  Lung Cancer Subtypes Generate Unique Immune Responses.

Authors:  Stephanie E Busch; Mark L Hanke; Julia Kargl; Heather E Metz; David MacPherson; A McGarry Houghton
Journal:  J Immunol       Date:  2016-10-31       Impact factor: 5.422

5.  Tumor lymphocytic infiltration in non-small cell lung cancer: the ultimate prognostic marker?

Authors:  Laura Romero Vielva
Journal:  Transl Lung Cancer Res       Date:  2016-08

Review 6.  Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?

Authors:  Chethan Ramamurthy; James L Godwin; Hossein Borghaei
Journal:  Curr Treat Options Oncol       Date:  2017-06

Review 7.  SATB family chromatin organizers as master regulators of tumor progression.

Authors:  Rutika Naik; Sanjeev Galande
Journal:  Oncogene       Date:  2018-11-09       Impact factor: 9.867

Review 8.  The paradoxical role of tumor-infiltrating immune cells in lung cancer.

Authors:  Xiaodan Zheng; Yuhai Hu; Chengfang Yao
Journal:  Intractable Rare Dis Res       Date:  2017-11

9.  The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma.

Authors:  Joseph DiDomenico; Jonathan B Lamano; Daniel Oyon; Yuping Li; Dorina Veliceasa; Gurvinder Kaur; Leonel Ampie; Winward Choy; Jason B Lamano; Orin Bloch
Journal:  Oncoimmunology       Date:  2018-04-25       Impact factor: 8.110

Review 10.  B cell regulation of anti-tumor immune response.

Authors:  Yu Zhang; Richard Morgan; Eckhard R Podack; Joseph Rosenblatt
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.